Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.
Source: Pharmaceutical Technology, 2026-10-09. Third-party report, linked to its original publisher; IC360 has not independently verified it.
